Literature DB >> 6265365

Antibody to human adenovirus early antigens during acute adenovirus infections.

G Gerna, E Cattaneo, M G Revello, M Battaglia, G Achilli.   

Abstract

The antibody (Ab) response to human adenovirus (AV) early antigens (EA) in acute AV infections was studied by the immunoperoxidase antibody technique for determining virus-specific immunoglobulin G (IPA-IgG). AV-EA-Ab appeared about 5 days after the onset of clinical symptoms, reached a peak 15 to 30 days later, and declined in titer after a few months. The staining pattern in the IPA-IgG reaction was usually nuclear; however, in most primary infections sera obtained 2 to 3 weeks after the onset of infection also showed cytoplasmic staining. According to the recent deoxyribonucleic acid homology classification of human AV in five groups (A, B, C, D, and E), the EA-Ab response in primary human infections was found to be group specific for groups A to D, with consistent cross-reactions with group E. In AV type 4 (group E) infections, EA-Ab appeared to be directed against all groups, although at different titers. Comparable results were obtained using AV type-specific animal antisera. Thus, it was concluded that group E shares EA with all the other groups. Furthermore, in each individual with remote AV infections, the current infection elicited an anamnestic EA-Ab response to all AV groups responsible for previous infections. In diagnostic virology these findings can be applied to the rapid diagnosis of a current for recent) AV infection on a single serum sample and to the rapid group identification of clinical isolates by using type-specific animal antisera containing EA-Ab (one for each group) or sera from patients with primary AV infections.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6265365      PMCID: PMC351513          DOI: 10.1128/iai.32.2.778-787.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  The presence of antibodies in human serum to early (T) adenovirus antigens.

Authors:  A M Lewis; W H Wiese; W P Rowe
Journal:  Proc Natl Acad Sci U S A       Date:  1967-03       Impact factor: 11.205

2.  Thirty-one human adenovirus serotypes (Ad1-Ad31) form five groups (A-E) based upon DNA genome homologies.

Authors:  M Green; J K Mackey; W S Wold; P Rigden
Journal:  Virology       Date:  1979-03       Impact factor: 3.616

3.  Neutralizing, hemagglutination-inhibiting and group complement-fixing antibody responses in human adenovirus infections.

Authors:  N J Schmidt; E H Lennette; C J King
Journal:  J Immunol       Date:  1966-07       Impact factor: 5.422

4.  Further subgrouping of the human adenoviruses by differential hemagglutination.

Authors:  J C Hierholzer
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

5.  Detection of adenovirus type 12 neoantigen (s) in a continuous human amnion cell line (FL) by immunofluorescence.

Authors:  J L Riggs; N Takemori; E H Lennette
Journal:  Proc Soc Exp Biol Med       Date:  1965-12

6.  Standardized viral hemagglutination and hemagglutination-inhibition tests. II. Description and statistical evaluation.

Authors:  J C Hierholzer; M T Suggs; E C Hall
Journal:  Appl Microbiol       Date:  1969-11

7.  The early stages of absorption of injected horseradish peroxidase in the proximal tubules of mouse kidney: ultrastructural cytochemistry by a new technique.

Authors:  R C Graham; M J Karnovsky
Journal:  J Histochem Cytochem       Date:  1966-04       Impact factor: 2.479

8.  Classification of human adenoviruses by SDS-polyacrylamide gel electrophoresis of structural polypeptides.

Authors:  G Wadell
Journal:  Intervirology       Date:  1979       Impact factor: 1.763

9.  Nonspecific inhibitors of coronavirus OC43 haemagglutination in human sera.

Authors:  T Hovi
Journal:  Med Microbiol Immunol       Date:  1978-11-17       Impact factor: 3.402

10.  IMMUNOFLUORESCENT STUDIES OF ADENOVIRUS 12 TUMORS AND OF CELLS TRANSFORMED OR INFECTED BY ADENOVIRUSES.

Authors:  J H POPE; W P ROWE
Journal:  J Exp Med       Date:  1964-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.